Skip to main content
Premium Trial:

Request an Annual Quote

BD Preliminary Fiscal Q1 Revenues Up 35 Percent on Continued Bard Boost

NEW YORK (GenomeWeb) – Becton Dickinson reported today that preliminary estimates show fiscal first quarter revenues increased 35 percent, primarily due to the acquisition of C.R. Bard.

The firm reported preliminary revenues of $4.16 billion, compared to $3.08 billion in fiscal Q1 of 2018. On a currency-neutral basis, including revenues of Bard in both the current and past fiscal year, revenues increased 5 percent. Analysts had estimated first quarter revenues of $4.11 billion.

It estimated preliminary diluted earnings per share at $2.05 compared to a loss of $.76 in the prior year. Adjusted EPS was preliminarily reported to be $2.70 year-over-year compared to EPS of $2.48 in the firm's fiscal Q1 last year, which would beat the consensus Wall Street estimate of $2.61. The firm attributed the increase to the timing of certain tax items and better-than-expected performance across all three business segments.

The company reaffirmed previously issued guidance of 8.5 to 9.5 percent revenue growth, primarily due to the Bard acquisition, with 5 to 6 percent growth on a comparable, currency-neutral basis that includes Bard revenues in fiscal 2019 and the full fiscal year 2018. BD completed the acquisition of Bard in late 2017, during its fiscal second quarter.

BD has also guided for fiscal year 2019 adjusted diluted EPS of between $12.05 and $12.15, which would represent roughly 10 percent growth year over year.

On the Nasdaq, BD's shares were up about 2 percent in Thursday morning trade at $234.80.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.